Publication

Allogeneic beta-islet cells correct diabetes and resist immune rejection

Publications associées (30)

Overcoming immunological barriers in regenerative medicine

Regenerative therapies that use allogeneic cells are likely to encounter immunological barriers similar to those that occur with transplantation of solid organs and allogeneic hematopoietic stem cells (HSCs). Decades of experience in clinical transplantati ...

Nature Publishing Group2014

Device design and materials optimization of conformal coating for islets of Langerhans

Jeffrey Alan Hubbell, Alice Anna Tomei

Encapsulation of islets of Langerhans may represent a way to transplant islets in the absence of immunosuppression. Traditional methods for encapsulation lead to diffusional limitations imposed by the size of the capsules (600-1,000 m in diameter), which r ...

National Academy of Sciences2014

Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes

Jeffrey Alan Hubbell, Melody Swartz, Alexandre de Titta, Marie Ballester, Patricia Corthésy Henrioud, Pedro Romero, Laura Jeanbart

The sentinel or tumor-draining lymph node (tdLN) serves as a metastatic niche for many solid tumors and is altered via tumor-derived factors that support tumor progression and metastasis. tdLNs are often removed surgically, and therapeutic vaccines against ...

Amer Assoc Cancer Research2014

Targeting and Modulating Tumor-Associated Sites with Novel Nanoparticle-Based Immunotherapies

Laura Jeanbart

Cancer is a global disease and a leading cause of death worldwide. While surgery, radiotherapy and chemotherapy comprise the classical tools to eradicate tumors, they do not cure cancer, cannot prevent metastases, lead to side effects, and most importantly ...

EPFL2013

Device for application of medium to human tissue or animal body such as eye, has carrier which is provided with micro-cavity for containing medium in direct contact with object on which medium is to be applied

Hubert van den Bergh, Philippe Renaud, Yann Barrandon, Thomas Michael Braschler, Julien Graber

NOVELTY - The device has a carrier (1) which is provided with micro-cavity (2) for containing medium in direct contact with the object on which the medium is to be applied. Other carrier is provided with ring to protect the medium from environment when the ...

2013

Proangiogenic Hydrogels Within Macroporous Scaffolds Enhance Islet Engraftment in an Extrahepatic Site

Mikaël Martino, Jeffrey Alan Hubbell

The transplantation of allogeneic islets in recent clinical trials has shown substantial promise as a therapy for type 1 diabetes; however, long-term insulin independence remains inadequate. This has been largely attributed to the current intravascular, he ...

Mary Ann Liebert, Inc2013

Engineering antigens for in situ erythrocyte binding induces T-cell deletion

Jeffrey Alan Hubbell, Stephane Kontos, Iraklis Kourtis, Karen Dane

Antigens derived from apoptotic cell debris can drive clonal T-cell deletion or anergy, and antigens chemically coupled ex vivo to apoptotic cell surfaces have been shown correspondingly to induce tolerance on infusion. Reasoning that a large number of ery ...

Natl Acad Sciences2013

Therapeutic Immunomodulation of the Lymphoid-like Tumor Environment Using Nanoparticulate Formulations

Iraklis Kourtis

Cancer is a leading cause of death worldwide. Understanding the underlying mechanisms that lead to tumor escape and evasion is pivotal for the design of new therapeutic applications. This thesis takes an immunobioengineering approach, and navigates through ...

EPFL2012

Immune Engineering Via Differential Antigen Carriers and Co-Stimulatory Molecules

Jackson Eby

There is an increasing clinical need for vaccines capable of enhancing antigen-specific immune responses and treatments that can induce immunological tolerance toward a single antigen. Here we explore two platforms to enhance either immunization or toleriz ...

EPFL2012

Engineering Erythrocyte Affinity for Improved Pharmacokinetics and Immune Tolerogenesis

Stephane Kontos

The clinical success of recombinant protein therapeutics in the treatment of disease is a hallmark of modern medical research, yet there remain numerous unaddressed issues regarding their delivery and immunogenicity. Regardless of in vivo efficacy, the bio ...

EPFL2011